Title: Deepening the Reform of the Review and Approval System and Encouraging the Innovation of Drugs in China
Speaker : Ruyi He, MD; Chief Scientist, Center for Drug Evaluation (CDE), Chinese Food and Drug Administration (CFDA)
Introducing current policies on the Reform of the Review and Approval System in China, especially introducing the guidances on encouraging the Innovation of Drugs in China, such as IND application and conditional approval etc.
Dr. Ruyi He is Chief Scientist of Center for Drug Evaluation (CDE), Chinese Food and Drug Administration (CFDA). Dr. He has rich drug regulatory experience and had worked for FDA in the U.S. for 17 years. Before joining CDE/CFDA, he was Medical Officer, Medical Team Leader and Acting Deputy Division Director in the Division of Gastroenterology and Inborn Errors Products, Center for Drug Evaluation and Research, FDA in the U.S.. Previously, Dr. He served as Staff Scientist at National Institutes of Health (NIH) in the U.S..
Dr. He received his M.D. intern and residency training in the Howard University Hospital, Washington DC. Dr. He is a board certified physician for internal medicine and licensed in the State of of Virginia and West Virginia. I